Drug Type Biosimilar, Monoclonal antibody |
Synonyms Dupilumab Biosimilar (China Resources Biopharmaceutical Co., Ltd.), 度普利尤单抗生物类似药(华润生物医药有限公司) |
Target |
Action inhibitors |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Severe Atopic Dermatitis | IND Approval | China | 24 Mar 2026 |






